Allergan announces resolution concluding federal investigation into Warner Chilcott sales and marketing practices

Under the settlement agreements, Warner Chilcott Sales will pay a total of approximately $102 million, plus interest, to the federal government and the states to resolve civil claims.

Under the settlement agreements, Warner Chilcott Sales will pay a total of approximately $102 million, plus interest, to the federal government and the states to resolve civil claims. The settlements will resolve claims regarding a range of alleged sales and marketing activities by Warner Chilcott Sales.

In addition to the civil settlement, Warner Chilcott Sales agreed to plead guilty to a charge of health care fraud in violation of 18 U.S.C. §1347 related to certain of the company's sales and marketing practices prior to its acquisition by Allergan. In connection with the criminal plea, Warner Chilcott Sales will pay a total of approximately $23 million in criminal fines and forfeiture amounts.

The company previously recorded charges of approximately $125 million in connection with the government's investigation.

Following its acquisition of Warner Chilcott Sales, Allergan fully co-operated in the government's investigation and in reaching these civil settlements and plea agreement.

"At Allergan we take seriously our responsibility and commitment to abide by all US and international laws that govern the sales, marketing, education and promotion of our products, and recognize the tremendous impact that this responsibility has on the customers and patients we serve," said Brent Saunders, President and CEO of Allergan. "Our company's culture is deeply rooted in compliance, and we recognize the importance of a strong compliance program. We have focused on developing and implementing a best-in-class set of compliance policies and procedures, and we remain committed to running our business in full compliance with the regulations and high ethical standards we have set for Allergan."